Abderrahim El Guerrab

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer